### International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 03 Issue 09 September 2023

Page No: 2080-2085

DOI: https://doi.org/10.47191/ijmscrs/v3-i9-49, Impact Factor: 6.597

# Introduction to Vaginal Microbiota and its Relevance in Gynecological Health

Fernando Hernandez Vespero<sup>1</sup>, Edgar Josue Alvarez Alcala<sup>2</sup>, Danielle López Fernández<sup>3</sup>, Vicente Adrian Lopez Esparza<sup>2</sup>, Alejandro Rafael Almeida Návar<sup>3</sup>

<sup>1</sup>Escuela de Medicina, Instituto Politecnico Nacional

<sup>2</sup>Universidad Autónoma de Guadalajara

<sup>3</sup>Universidad Autónoma de Baja California

ABSTRACT	ARTICLE DETAILS
This article provides an introductory exploration into the vaginal microbiota and its significance in maintaining gynecological health. The vaginal microbiota plays a crucial role in sustaining a balanced and harmonious vaginal ecosystem, influencing various aspects of reproductive well-being. By examining the composition and dynamics of the vaginal microbiota, this article highlights its impact on preventing dysbiosis and associated infections. A deeper understanding of the intricate interactions within the vaginal microbiota can pave the way for targeted therapeutic interventions aimed at promoting and preserving gynecological health.	Published On: 28 September 2023
<b>KEYWORDS:</b> vaginal microbiota, gynecological health, microbial balance, vaginal ecosystem, dysbiosis, infections, therapeutic interventions.	Available on: <u>https://ijmscr.org/</u>

### INTRODUCTION

The vaginal microbiota refers to the collection of microorganisms that inhabit the vagina. It plays a crucial role in maintaining women's health by promoting a balanced vaginal environment and protecting against infections. The microbiota is composed of various bacterial species, with lactobacilli being the most predominant in healthy women [<sup>1</sup>]. The diversity and composition of the vaginal microbiota in healthy women are important factors for maintaining vaginal health. Lactobacilli, such as Lactobacillus crispatus, are typically the main community state types in the vagina [1]. They contribute to the acidification of the vaginal milieu by producing lactic acid, which helps to maintain a low pH and prevent the overgrowth of harmful bacteria  $[^2]$ . The relative ratio of different forms of lactic acid in the vaginal microbiota is believed to provide stability and resistance to infections [<sup>1</sup>]. In addition to lactobacilli, healthy women may also have a non-lactobacillary microbiota, although the rate of occurrence may vary based on ethnicity [1]. The vaginal microbiota is influenced by various factors, including exogenous and endogenous factors, such as hormonal changes, sexual activity, and hygiene practices [<sup>1</sup>].

Maintaining a diverse and balanced vaginal microbiota is essential for women's health. Imbalances in the microbiota, such as a decrease in lactobacilli and an increase in other bacterial species, have been associated with various gynecological conditions, including bacterial vaginosis (BV) [<sup>2</sup>]. BV is characterized by an overgrowth of harmful bacteria and can lead to symptoms like abnormal vaginal discharge, itching, and odor [<sup>2</sup>].

It is important to note that the definition of a healthy vaginal microbiota is not solely based on the presence or absence of individual microorganisms. The composition, diversity, and functional attributes of the microbiota are all important factors for maintaining vaginal health [<sup>1</sup>]. Further research is needed to better understand the complexity of the vaginal microbiota and its role in women's health.

### METHODOLOGY

To explore the significance of vaginal microbiota in gynecological health, this study will utilize a comprehensive methodology involving literature review and analysis. The primary objective is to understand the role of vaginal microbiota in maintaining gynecological well-being and its potential implications for various health conditions.

A systematic search will be conducted across reputable scientific databases, including PubMed, Web of Science, and Scopus. The search scope will encompass articles published

in English between January 2010 and July 2023. Controlled vocabulary (MeSH terms) and relevant keywords related to vaginal microbiota and gynecological health will be employed. The search strategy will involve the use of Boolean operators and proximity terms. Some of the key terms to be used are: Vaginal microbiota, Vaginal flora, Gynecological health, Reproductive tract microbiome, Vaginal dysbiosis, Vaginal pH, Vaginal infections.

Studies not directly addressing the influence of vaginal microbiota on gynecological health and those not relevant to the research question will be excluded from the review.

Two independent reviewers will evaluate the titles and abstracts of the identified articles from the initial search. Any discrepancies between reviewers will be resolved through consensus or consultation with a third reviewer if necessary. Articles deemed relevant will undergo a thorough full-text assessment to determine alignment with the inclusion criteria. Data extracted from the selected studies will encompass information concerning the relationship between vaginal microbiota and gynecological health. A narrative synthesis approach will be employed to summarize and analyze the findings, highlighting key associations between vaginal microbiota composition and various gynecological conditions. Potential mechanisms through which vaginal microbiota may impact gynecological health will be explored.

The results will be presented in a narrative format, describing the relevance of vaginal microbiota in gynecological health. Specific examples of alterations in vaginal microbiota composition and their potential implications for conditions such as vaginal infections, bacterial vaginosis, and other relevant health issues will be provided.

The review will acknowledge potential limitations, including variations in study methodologies, sample sizes, and methods of assessing vaginal microbiota composition across different studies.

### The protective role of the vaginal microbiota

The vaginal microbiota plays a crucial role in protecting against pathogens and maintaining vaginal balance. Lactobacilli, a type of bacteria commonly found in the vagina, are particularly important in this process.

The vaginal microbiota consists of various microbial species, with lactobacilli being the predominant bacteria in a healthy vagina [<sup>1</sup>]. These beneficial bacteria produce lactic acid, creating an acidic environment (low pH) in the vagina. This acidic environment inhibits the growth of harmful pathogens, such as bacteria and fungi, by creating an unfavorable habitat for their survival and replication [<sup>1</sup>] [<sup>3</sup>].

Lactobacilli also produce hydrogen peroxide (H2O2) [<sup>4</sup>]. H2O2-producing lactobacilli are associated with a lower risk of bacterial vaginosis (BV), a condition characterized by an overgrowth of harmful bacteria in the vagina [<sup>4</sup>]. BV is known to disrupt the normal vaginal microbiota and increase the risk of acquiring sexually transmitted infections (STIs) and other gynecological diseases [<sup>5</sup>].

In addition to maintaining a healthy vaginal environment, lactobacilli also interact with the immune system. They stimulate the production of local immune factors, such as cytokines and antibodies, which help to maintain a balanced immune response in the vagina [<sup>4</sup>]. Lactobacilli-specific immune sensitization has been observed in adolescents, indicating an immune response specifically targeted towards these beneficial bacteria [<sup>4</sup>].

However, it is important to note that the composition of the vaginal microbiota can vary among individuals and can be influenced by factors such as hormonal changes, sexual activity, hygiene practices, and the use of antibiotics [<sup>1</sup>]. Disruptions in the vaginal microbiota, such as a decrease in lactobacilli or an overgrowth of harmful bacteria, can lead to dysbiosis and an increased susceptibility to infections.

In summary, lactobacilli play a crucial role in maintaining vaginal balance and protecting against pathogens. They create an acidic environment, produce hydrogen peroxide, and interact with the immune system to promote a healthy vaginal microbiota. Further research is needed to fully understand the complex interactions between lactobacilli, the vaginal microbiota, and overall vaginal health.

### Imbalance of the vaginal microbiota and its consequences

Bacterial vaginosis (BV) is a common vaginal infection that occurs when there is an imbalance in the vaginal microbiota. It is characterized by a decrease in the number of beneficial lactobacilli bacteria and an overgrowth of other bacteria. The exact cause of BV is still unclear, but it is believed to be multifactorial [<sup>6</sup>].

Symptoms of BV may include a thin, grayish-white vaginal discharge with a strong fishy odor, itching, and irritation. However, many women with BV may not experience any symptoms [<sup>6</sup>].

BV is not considered a sexually transmitted infection, but it has been associated with high-risk sexual behaviors such as having multiple sexual partners and recent changes in sexual partners. Other risk factors include douching, smoking, and a history of pregnancy [<sup>7</sup>].

The treatment for BV usually involves antibiotics, such as metronidazole or clindamycin, which can be taken orally or applied topically. These medications help to restore the balance of bacteria in the vagina. It is important to complete the full course of treatment, even if symptoms improve, to prevent recurrence [<sup>8</sup>].

Yeast infections, also known as vaginal candidiasis, are another common type of vaginal infection. They are caused by an overgrowth of the fungus Candida albicans in the vagina. Yeast infections can cause symptoms such as itching, burning, and a thick, white vaginal discharge [<sup>9</sup>].

While BV and yeast infections are both vaginal infections, they are caused by different microorganisms. However, changes in the vaginal microbiota can increase the risk of both infections. For example, the use of antibiotics to treat

BV can disrupt the balance of bacteria in the vagina and increase the risk of developing a yeast infection  $[^{10}]$ .

### Influence of external factors on the vaginal microbiota

The vaginal microbiota can be influenced by various external factors, such as antibiotics, the menstrual cycle, hormonal fluctuations, and sexual practices.

Antibiotics: The use of antibiotics can disrupt the balance of the vaginal microbiota by reducing the levels of beneficial lactobacilli and allowing for the overgrowth of opportunistic pathogens [<sup>2</sup>]. This can lead to conditions like bacterial vaginosis (BV), characterized by an overgrowth of harmful bacteria.

Menstrual Cycle: The composition of the vaginal microbiota can vary throughout the menstrual cycle. During the follicular phase (before ovulation), estrogen levels increase, leading to the thickening of the vaginal lining and an increase in glycogen production. This promotes the growth of lactobacilli, which produce lactic acid and help maintain a healthy acidic pH. However, during the luteal phase (after ovulation), progesterone levels rise, causing a decrease in glycogen and lactobacilli, which can lead to a shift in the vaginal microbiota [<sup>1</sup>].

Hormonal Fluctuations: Hormonal fluctuations, such as those that occur during pregnancy or menopause, can also impact the vaginal microbiota. In menopause, the decline in estrogen levels can lead to vaginal atrophy, reduced abundance of lactobacilli, and an increased risk of infections [<sup>2</sup>]. Pregnancy is associated with changes in the vaginal microbiota, with decreased lactobacilli and increased diversity [<sup>11</sup>].

Sexual Practices: Sexual practices can influence the vaginal microbiota. Certain sexual behaviors, such as unprotected sex, multiple sexual partners, and douching, have been associated with an increased risk of disturbances in the vaginal microbiota and the development of BV [<sup>12</sup>]. Additionally, the presence of certain sexually transmitted infections (STIs), such as Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium, can also impact the vaginal microbiota [<sup>13</sup>].

## The role of the vaginal microbiota during significant events in a woman's life

The vaginal microbiota plays a crucial role in maintaining the health of a woman's reproductive system and can be influenced by significant events such as pregnancy and menopause. During pregnancy, the vaginal microbiota undergoes subtle changes. Studies have shown that a lactobacilli-dominated microbiome is associated with a lower risk of preterm birth [<sup>14</sup>]. The composition of the vaginal microbiota during pregnancy changes as gestational age progresses, with an increase in the relative abundance of certain Lactobacillus species [<sup>15</sup>]. However, it is important to note that the vaginal microbiota of pregnant women who subsequently have a preterm delivery does not differ significantly from those who have a term delivery [<sup>15</sup>].

During menopause, the decline in estrogen levels can affect the vaginal microbiota. Estrogen loss is associated with vaginal atrophy, reduced abundance of Lactobacilli, and an increased amount of other bacterial species [<sup>2</sup>]. This shift in the vaginal microbiota composition can lead to an increased risk of genitourinary symptoms of menopause, such as vaginal dryness and low libido [<sup>14</sup>]. Estrogens also influence vaginal immunity through known and unknown mechanisms, further impacting the interplay between the vaginal microbiota and the immune system [<sup>2</sup>].

### Vaginal microbiota and sexually transmitted diseases (STDs)

The composition of the vaginal microbiota can indeed affect susceptibility and resistance to sexually transmitted diseases (STDs).

Several studies have investigated the association between vaginal microbiota and various STDs.

One study conducted in Russia found a significant association between bacterial vaginosis (BV)-associated vaginal microbiota and the presence of Chlamydia trachomatis, Mycoplasma genitalium, and Trichomonas vaginalis infections [<sup>13</sup>]. Another study conducted a narrative review and summarized the literature data related to vaginal microbiota and gynecological diseases. It highlighted the role of altered microbiota and the interplay between microbiota and the immune system in several gynecologic conditions, including STDs [<sup>2</sup>].

Furthermore, a study comparing the vaginal microbiota of women engaged in high-risk sexual behavior (sex work) with women who were not engaged in high-risk sexual behavior found that a diverse vaginal microbiota with low abundance of Lactobacillus species was associated with increased prevalence of STDs, including HPV and high-risk HPV [<sup>12</sup>]. Additionally, a systematic review and meta-analysis explored the association between vaginal microbiota and various STDs. It found that a low-Lactobacillus vaginal microbiota (LL-VMB) was associated with increased risk of HPV, Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium infections [<sup>16</sup>].

Although more research is needed to fully understand the mechanisms underlying these associations, these findings suggest that the vaginal microbiota composition can be a key factor in the prevention and treatment of STDs. Further studies are warranted to explore the potential of modulating the vaginal microbiota as a strategy for STD prevention and treatment.

### Therapies and treatments to restore and maintain a healthy vaginal microbiota

There are various therapies and treatments available to restore and maintain a healthy vaginal microbiota. One approach is the use of probiotics, which are live microorganisms that can confer health benefits when administered in adequate amounts. Probiotics work by promoting the growth of

beneficial bacteria and inhibiting the growth of harmful bacteria in the vagina.

Several studies have explored the potential of probiotics in improving vaginal health. For example, a study found that oral probiotics containing Lactobacillus acidophilus and Lactobacillus rhamnosus can colonize the vagina and restore a normal vaginal microbiota [<sup>17</sup>]. Another study showed that oral probiotics can decrease the pH and Nugent score, indicating a normalization of the vaginal microbiota [<sup>18</sup>]. Additionally, probiotics have been found to reduce the risk of bacterial vaginosis (BV) and improve symptoms of abnormal vaginal microbiota [<sup>17</sup>].

Preventive and treatment strategies based on microbiota modulation are also being explored. For instance, the use of probiotics has shown promise in preventing recurrent vulvovaginal infections (RVVI) [<sup>20</sup>]. Probiotics can help restore a healthy vaginal microbiota, which may reduce the risk of RVVI. Furthermore, probiotics have been studied in the context of preventing preterm birth, as an abnormal vaginal microbiota composition has been associated with preterm birth [<sup>21</sup>].

### Recent advances and future directions in vaginal microbiota research

Recent advances in research on vaginal microbiota have provided valuable insights into its composition, dynamics, and impact on women's health. Several studies have focused on understanding the structure and functioning of the vaginal microbiome [<sup>1</sup>]. These studies have revealed that the vaginal microbiota is primarily composed of lactobacilli, which play a crucial role in maintaining a healthy vaginal environment. Lactobacilli produce lactic acid, which helps maintain an acidic pH that inhibits the growth of harmful bacteria [<sup>1</sup>].

Furthermore, research has shown that the vaginal microbiota undergoes subtle changes during pregnancy, and these changes may affect pregnancy outcomes [<sup>11</sup>]. Studies have highlighted the association between the vaginal microbiota and conditions such as bacterial vaginosis (BV), pelvic inflammatory disease (PID), preterm labor, and cervical dysplasia [<sup>2</sup>] [<sup>12</sup>] [<sup>22</sup>].

To study the vaginal microbiota, researchers have utilized various techniques and tools. High-throughput sequencing, such as Illumina-MiSeq sequencing, has been employed to analyze the 16S rRNA gene amplicons and characterize the vaginal and gut microbiota [<sup>11</sup>]. Other techniques include PCR-DGGE population profiling and gene-specific primers hybridization  $\begin{bmatrix} 23 \end{bmatrix} \begin{bmatrix} 24 \end{bmatrix}$ . These techniques allow for the identification and quantification of specific bacterial species in the vaginal microbiota. present Future directions in research on vaginal microbiota include exploring the interplay between the microbiota and the immune system in gynecological diseases [<sup>2</sup>]. Additionally, studies are needed to better understand the role of the vaginal microbiota in infertility and its potential as a biomarker for monitoring cervical carcinogenesis [<sup>25</sup>] [<sup>26</sup>].

Based on the growing understanding of the vaginal microbiota, there is potential for the development of future treatments and therapies that focus on modulating the microbiota. Probiotics, specifically lactobacilli strains, have shown promise in preventing and treating vaginal infections such as bacterial vaginosis [<sup>17</sup>]. Oral intake of lactobacilli/lactoferrin complexes has been found to restore normal vaginal microbiota and improve symptoms of abnormal vaginal microbiota [<sup>17</sup>]. However, further research is needed to fully explore the therapeutic potential of modulating the vaginal microbiota.

#### CONCLUSION

The vaginal microbiota plays a vital role in maintaining gynecological health by creating a balanced and protective environment within the vagina. Predominantly composed of lactobacilli, these beneficial bacteria contribute to the production of lactic acid and hydrogen peroxide, creating an acidic environment that inhibits the growth of harmful pathogens. The composition and diversity of the vaginal microbiota are essential for preventing conditions like bacterial vaginosis (BV) and maintaining overall reproductive well-being.

External factors such as antibiotics, hormonal fluctuations, menstrual cycle phases, and sexual practices can disrupt the delicate balance of the vaginal microbiota, increasing the risk of infections and gynecological issues. Events such as pregnancy and menopause further impact the vaginal microbiota, highlighting its significance in various life stages. Recent research has illuminated the connections between the vaginal microbiota and sexually transmitted infections (STIs). Studies suggest that a balanced microbiota is associated with reduced susceptibility to certain STIs, while imbalances increase the risk. Probiotics have emerged as a potential therapeutic intervention for restoring and maintaining a healthy vaginal microbiota, with promising results in preventing and treating conditions like BV and recurrent infections.

Advances in technology have enabled a deeper understanding of the vaginal microbiota's complexity and its impact on women's health. However, further research is needed to unravel its intricate interactions with the immune system, fertility, and the development of gynecological diseases. The potential for targeted interventions to modulate the vaginal microbiota offers an exciting avenue for improving gynecological health and overall well-being.

### REFERENCES

- I. Buchta V. Vaginal microbiome. Ceska Gynekol. 2018;83(5):371-379.
- II. Villa P, Cipolla C, D'Ippolito S, et al. The interplay between immune system and microbiota in gynecological diseases: a narrative review. Eur Rev Med Pharmacol Sci. 2020;24(10):5676-5690. doi:10.26355/eurrev\_202005\_21359

- III. Hemalatha R, Mastromarino P, Ramalaxmi BA, Balakrishna NV, Sesikeran B. Effectiveness of vaginal tablets containing lactobacilli versus pH tablets on vaginal health and inflammatory cytokines: a randomized, double-blind study. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2012;31(11):3097-3105. doi:10.1007/s10096-012-1671-1
- IV. Alvarez-Olmos MI, Barousse MM, Rajan L, et al. Vaginal lactobacilli in adolescents: presence and relationship to local and systemic immunity, and to bacterial vaginosis. Sex Transm Dis. 2004;31(7):393-400. doi:10.1097/01.olq.0000130454.83883.e9
- V. Martin HL, Richardson BA, Nyange PM, et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis. 1999;180(6):1863-1868. doi:10.1086/315127
- VI. Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis. 2007;34(11):864-869. doi:10.1097/OLO.0b013e318074e565
- VII. Bradshaw CS, Morton AN, Garland SM, Morris MB, Moss LM, Fairley CK. Higher-risk behavioral practices associated with bacterial vaginosis compared with vaginal candidiasis. Obstet Gynecol. 2005;106(1):105-114. doi:10.1097/01.AOG.0000163247.78533.7b
- VIII. Armstrong E, Hemmerling A, Joag V, et al. Treatment Success Following Standard Antibiotic Treatment for Bacterial Vaginosis Is Not Associated With Pretreatment Genital Immune or Microbial Parameters. Open Forum Infect Dis. 2023;10(1):ofad007. doi:10.1093/ofid/ofad007
- IX. Haahr T, Zacho J, Bräuner M, Shathmigha K, Skov Jensen J, Humaidan P. Reproductive outcome of patients undergoing in vitro fertilisation treatment and diagnosed with bacterial vaginosis or abnormal vaginal microbiota: a systematic PRISMA review and meta-analysis. BJOG Int J Obstet Gynaecol. 2019;126(2):200-207.

doi:10.1111/1471-0528.15178

- X. Pawlaczyk M, Friebe Z, Pawlaczyk MT, Sowinska-Przepiera E, Wlosinska J. The effect of treatment for vaginal yeast infection on the prevalence of bacterial vaginosis in early pregnancy. Acta Dermatovenerol Croat ADC. 2006;14(1):26-29.
- XI. Vasundhara D, Raju VN, Hemalatha R, Nagpal R, Kumar M. Vaginal & gut microbiota diversity in pregnant women with bacterial vaginosis & effect of oral probiotics: An exploratory study. Indian J Med Res. 2021;153(4):492-502.

doi:10.4103/ijmr.IJMR\_350\_19

- XII. Association of high-risk sexual behaviour with diversity of the vaginal microbiota and abundance of Lactobacillus - PubMed. Accessed August 18, 2023. https://pubmed.ncbi.nlm.nih.gov/29095928/
- XIII. Shipitsyna E, Khusnutdinova T, Budilovskaya O, et al. Bacterial vaginosis-associated vaginal microbiota is an age-independent risk factor for Chlamydia trachomatis, Mycoplasma genitalium and Trichomonas vaginalis infections in low-risk women, St. Petersburg, Russia. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2020;39(7):1221-1230.

 $doi{:}10.1007/s10096{\text{-}}020{\text{-}}03831{\text{-}}w$ 

- XIV. Shardell M, Gravitt PE, Burke AE, Ravel J, Brotman RM. Association of Vaginal Microbiota With Signs and Symptoms of the Genitourinary Syndrome of Menopause Across Reproductive Stages. J Gerontol A Biol Sci Med Sci. 2021;76(9):1542-1550. doi:10.1093/gerona/glab120
- XV. Romero R, Hassan SS, Gajer P, et al. The vaginal microbiota of pregnant women who subsequently have spontaneous preterm labor and delivery and those with a normal delivery at term. Microbiome. 2014;2:18. doi:10.1186/2049-2618-2-18
- XVI. Tamarelle J, Thiébaut ACM, de Barbeyrac B, Bébéar C, Ravel J, Delarocque-Astagneau E. The vaginal microbiota and its association with human papillomavirus, Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium infections: a systematic review and meta-analysis. Clin Microbiol Infect Off Publ Eur Soc Clin Dis. Microbiol Infect 2019;25(1):35-47. doi:10.1016/j.cmi.2018.04.019
- XVII. Russo R, Edu A, De Seta F. Study on the effects of an oral lactobacilli and lactoferrin complex in women with intermediate vaginal microbiota. Arch Gynecol Obstet. 2018;298(1):139-145. doi:10.1007/s00404-018-4771-z
- XVIII. Tomusiak A, Strus M, Heczko PB, et al. Efficacy and safety of a vaginal medicinal product containing three strains of probiotic bacteria: a multicenter, randomized, double-blind, and placebo-controlled trial. Drug Des Devel Ther. 2015;9:5345-5354. doi:10.2147/DDDT.S89214
  - XIX. Husain S, Allotey J, Drymoussi Z, et al. Effects of oral probiotic supplements on vaginal microbiota during pregnancy: a randomised, double-blind, placebo-controlled trial with microbiome analysis.
    BJOG Int J Obstet Gynaecol. 2020;127(2):275-284. doi:10.1111/1471-0528.15675
  - XX. Kalia N, Singh J, Kaur M. Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review. Ann Clin Microbiol

Antimicrob. 2020;19(1):5. doi:10.1186/s12941-020-0347-4

XXI. Singer M, Borg M, Ouburg S, Morré SA. The relation of the vaginal microbiota to early pregnancy development during in vitro fertilization treatment-A meta-analysis. J Gynecol Obstet Hum Reprod. 2019;48(4):223-229.

doi:10.1016/j.jogoh.2019.01.007

- XXII. Norenhag J, Du J, Olovsson M, Verstraelen H, Engstrand L, Brusselaers N. The vaginal microbiota, human papillomavirus and cervical dysplasia: a systematic review and network meta-analysis. BJOG Int J Obstet Gynaecol. 2020;127(2):171-180. doi:10.1111/1471-0528.15854
- XXIII. Vitali B, Cruciani F, Baldassarre ME, et al. Dietary supplementation with probiotics during late pregnancy: outcome on vaginal microbiota and

cytokine secretion. BMC Microbiol. 2012;12:236. doi:10.1186/1471-2180-12-236

- XXIV. Sun D, Zhao X, Pan Q, et al. The association between vaginal microbiota disorders and early missed abortion: A prospective study. Acta Obstet Gynecol Scand. 2022;101(9):960-971. doi:10.1111/aogs.14410
- XXV. Hong X, Ma J, Yin J, et al. The association between vaginal microbiota and female infertility: a systematic review and meta-analysis. Arch Gynecol Obstet. 2020;302(3):569-578. doi:10.1007/s00404-020-05675-3
- XXVI. Kang GU, Jung DR, Lee YH, et al. Potential Association between Vaginal Microbiota and Cervical Carcinogenesis in Korean Women: A Cohort Study. Microorganisms. 2021;9(2):294. doi:10.3390/microorganisms9020294